KDM6B
MOLECULAR TARGETlysine demethylase 6B
KDM6B (lysine demethylase 6B) is targeted by 5 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting KDM6B
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | n oxalylglycine | 3.43 | 30 |
| 2 | alvespimycin | 3.40 | 29 |
| 3 | Deferasirox | 0.69 | 1 |
| 4 | 19-((1'S,4'R)-4'-hydroxy-1'-methoxy-2'-oxopentyl)geldanamycin [Supplementary Concept] | 0.69 | 1 |
| 5 | triolimus [Supplementary Concept] | 0.69 | 1 |
About KDM6B as a Drug Target
KDM6B (lysine demethylase 6B) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 5 compounds with documented KDM6B interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
KDM6B inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.